Macquarie Group’s Atara Biotherapeutics ATRA Stock Holding History

Macquarie Group’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-197	Closed	-$1.68K	–	1671
2024 Q2	$1.68K	Buy	+197	New	+$2.96K	﹤0.01%	1815
2022 Q3	–	Sell	-26	Closed	-$2.92K	–	2493
2022 Q2	$5K	Hold	26	–	–	﹤0.01%	2518
2022 Q1	$6K	Hold	26	–	–	﹤0.01%	2567
2021 Q4	$10K	Sell	26 -106	-80%	-$44.6K	﹤0.01%	2506
2021 Q3	$59K	Buy	132 +101	+326%	+$36.2K	﹤0.01%	2176
2021 Q2	$12K	Hold	31	–	–	﹤0.01%	2450
2021 Q1	$11K	Sell	31 -15	-33%	-$6.63K	﹤0.01%	2376
2020 Q4	$22K	Hold	46	–	–	﹤0.01%	2203
2020 Q3	$15K	Hold	46	–	–	﹤0.01%	2216
2020 Q2	$17K	Buy	+46	New	+$11.6K	﹤0.01%	2209
2018 Q3	–	Sell	-76	Closed	-$70K	–	2155
2018 Q2	$70K	Buy	+76	New	+$81.6K	﹤0.01%	1907

Other funds holding ATRA

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Macquarie Group's ATRA Position: Q3 2024 in Review

Macquarie Group sold out of Atara Biotherapeutics (ATRA) in Q3 2024, closing a stake of 197 shares — an estimated $1.68K sold.

Macquarie Group first reported a position in ATRA in Q2 2018 and held it in 11 quarters. The position peaked at $70K in Q2 2018. 35 funds tracked by Wall St. Rank hold ATRA as of Q3 2024.

Macquarie Group reported no remaining Atara Biotherapeutics position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 197 Atara Biotherapeutics shares in Q3 2024, an estimated $1.68K.
Macquarie Group first reported a position in Atara Biotherapeutics in Q2 2018 and held it in 11 quarters.
Macquarie Group's Atara Biotherapeutics position peaked at $70K in Q2 2018.
35 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.